Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 5/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
| ▸ | GLS | O94925 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27477588 | 0.85 | EGFR (0.49) | PTGESEGFRERBB2MAPK8GLS | |
| SCHEMBL15065815 | 0.82 | NLRP3 (0.50) | CNR2SIGMAR1 | |
| SCHEMBL6136809 | 0.82 | EGFR (0.52) | PTGESEGFRERBB2MAPK8GLS | |
| SCHEMBL5690915 | 0.81 | EGFR (0.57) | EGFRERBB2MAPK8GLSSIGMAR1 | |
| SCHEMBL1632800 | 0.81 | GLS (0.49) | GLSCNR2KMT2A | |
| SCHEMBL12880514 | 0.81 | EPHX2 (0.58) | MAPK8CNR2SIGMAR1KMT2A | |
| SCHEMBL11626990 | 0.80 | EGFR (0.50) | PTGESEGFRERBB2MAPK8GLS | |
| SCHEMBL4057391 | 0.80 | POLB (0.52) | PTGESEGFRERBB2HSD17B10CNR2 | |
| SCHEMBL5871721 | 0.80 | KMT2A (0.69) | EGFRERBB2CNR2LMNAKMT2A | |
| SCHEMBL15831226 | 0.79 | POLB (0.58) | PTGESMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136552-A1 | ANTAGONISTS OF CAV 2.3 | LARIO THERAPEUTICS LIMITED (GB) | 2025-05-01 | — | — | US | disclosed |
| EP-4436664-A1 | ANTAGONISTS OF CAV 2.3 | Lario Therapeutics Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| WO-2023094828-A1 | ANTAGONISTS OF CAV 2.3 | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023094828-A1 | ANTAGONISTS OF CAV 2.3 | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136552-A1 | ANTAGONISTS OF CAV 2.3 | CACNA1E, CACNA1A, CACNA1S | PTGES 3444/4885EGFR 3545/4885ERBB2 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.